近日,国家药品监督管理局药品审评中心(CDE)官网显示,由兆科眼科与东曜药业联合提交的3.2类新药贝伐珠单抗眼内注射溶液(TAB014)的上市申请已获受理。TAB014用于治疗湿性老年性黄斑部病变(wAMD),数据显示,其是首个在国内申报上市的贝伐珠单抗眼科制剂,也是首个报产的针对wAMD的贝伐珠单抗。作为该创新药III期临床试验的核心服务伙伴,医渡科技为其提供一站式临床研究服务,包括运营、医学、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.